Also, Quizartinib demonstrates a longer median duration of CR at 38.6 months (95% CI: 21.9, NE) compared to placebo at 12.4 months (95% CI: 8.8, 22.7); these results led to FDA approval in July 2023 for patients newly diagnosed with FLT3-ITD AML [24,48]. The gene discussed is FLT3; the disease is acute myeloid leukemia.